Core Insights - Aon plc (AON) is experiencing growth through strategic acquisitions and partnerships, with strong new business growth and high client retention rates [1][2] Group 1: Growth Drivers - Aon achieves mid-single-digit organic revenue growth, supported by new business generation and client retention rates in the mid-90% range, with total revenues increasing by 9.4% year over year in 2025 [2] - The company enhances its global reach through high-return acquisitions, including the $13 billion NFP acquisition and partnerships in cybersecurity, which bolster its presence in high-demand areas [3] - Aon divests non-core businesses to focus on high-return segments, resulting in a trailing 12-month return on capital (ROC) of 15.7%, significantly above the industry average of 9% [4] Group 2: Strategic Initiatives - Aon's growth strategy is anchored in the disciplined execution of its 3x3 plan and the Aon United model, integrating risk and human capital capabilities, while investing in technology and operational consolidation [5] - Aon Business Services (ABS) serves as a central growth engine, enabling scalable analytics and AI deployment across geographies [5] Group 3: Financial Performance - Aon has demonstrated strong cash-generating abilities, repurchasing shares worth $1 billion in both 2024 and 2025, with $1.3 billion remaining under its share repurchase program [6] - The company has a robust earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 1% [7] Group 4: Financial Concerns - Operating expenses have risen significantly, with total expenses increasing by 8.9% in 2023, 23.7% in 2024, and 8.2% in 2025, driven by higher compensation and IT costs [8] - Aon ended the fourth quarter with cash and cash equivalents of $1.2 billion against a long-term debt of $14.7 billion, resulting in a long-term debt to capital ratio of 60.9%, higher than the industry average of 44.8% [9] - Interest expenses have also increased, jumping by 19.2% in 2023, 62.8% in 2024, and 3.4% in 2025 due to the company's debt-heavy balance sheet [10]

Core Viewpoint - Silver Point Capital has completely liquidated its position in Telephone and Data Systems (TDS), selling 857,000 shares valued at $33.63 million, indicating a significant shift in investment strategy [1][2]. Company Overview - Telephone and Data Systems, Inc. is a prominent U.S. telecommunications provider with a diverse portfolio that includes wireless, broadband, and cloud-based services [6]. - The company utilizes its national network infrastructure to provide connectivity and digital solutions to millions of customers [6]. Financial Performance - For the trailing twelve months (TTM), TDS reported revenue of $4.96 billion and a net income of -$28 million [4]. - The dividend yield stands at 0.35%, and the stock price as of February 17, 2026, was $46.54, reflecting a 15.97% increase over the past year [4][8]. Recent Developments - TDS experienced a transformative year, with fourth-quarter operating revenues from continuing operations rising to $330.7 million, up from $295.3 million the previous year [8]. - Net income attributable to common shareholders from continuing operations reached $37.2 million, or $0.32 per diluted share [8]. - The company has pivoted towards fiber and infrastructure, targeting an increase of 300,000 marketable fiber addresses, which alters its risk profile [10]. Strategic Changes - Management has sold its wireless business and launched Array as a tower platform, indicating a strategic shift in focus [10]. - The restructuring and divestitures may not align with the investment strategies of funds like Silver Point Capital, which are more concentrated in large positions [11].

Core Thesis - Post Holdings, Inc. is viewed as an overlooked investment opportunity with a market capitalization of approximately $5 billion, showcasing a strong history of value creation and capital allocation [3][4]. Financial Performance - Since its 2012 spin-off, Post has achieved high-teens revenue and cash flow growth, with a 13.4% compound annual growth rate (CAGR) in stock performance, outperforming peers in mature categories [4][6]. - The company currently trades at a valuation trough of approximately 8.8x EV/EBITDA, compared to an average of 11.7x, indicating a potentially attractive investment opportunity [4][7]. Business Operations - Post operates a diversified portfolio that includes branded cereals, pet food, foodservice egg and potato products, and the U.K.-based Weetabix business, which generates stable cash flows [5][6]. - The leadership team, including Chairman William Stiritz and CEO Robert Vitale, has a strong alignment with shareholders and employs a disciplined approach to capital allocation, focusing on M&A, divestitures, and share buybacks [6][7]. Future Outlook - Free cash flow is expected to increase as capital expenditures normalize and tax savings are realized, with potential cash generation equivalent to a significant portion of its market cap over the next five years [7]. - The company is positioned to achieve low- to mid-teens internal rates of return (IRRs) due to company-specific catalysts and a valuation that is well below historical norms [7].

Core Thesis - Kenvue Inc. is undergoing a strategic review to optimize its brand portfolio and enhance operating performance, aiming to unlock shareholder value [2][3][4] Company Overview - Kenvue Inc. operates as a consumer health company across multiple regions including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [2] - As of November 28th, Kenvue's share price was $17.35, with a market capitalization of approximately $30 billion and an enterprise value of around $38 billion [3] Financial Metrics - Kenvue's trailing and forward P/E ratios are 23.13 and 15.77 respectively, with an EV/EBITDA multiple of roughly 11× [1][3] - The company offers a dividend yield of about 4%, providing a solid income component for investors [3] Strategic Initiatives - The strategic review may lead to the sale of underperforming Skin Health & Beauty brands, acquisitions in high-growth OTC health categories, and capital reallocation to higher-margin segments [4] - Analysts estimate that these initiatives could raise Kenvue's margins and overall valuation by 15–25% [4] Investment Case - The combination of a disciplined strategic review, potential divestitures, and a focus on higher-margin segments positions Kenvue to enhance profitability and shareholder returns over time [5] - Kenvue's current valuation and dividend yield, along with strategic initiatives, create an attractive investment case for those seeking operational upside and a clear path to value creation [5]

Core Insights - The company has recently announced divestitures, specifically regarding Kepware and ThingWorx, which have raised questions about the strategic rationale behind these decisions [1] Group 1: Divestitures - The divestitures of Kepware and ThingWorx were influenced by a shift in the direction of these businesses, which has diverged from the company's core focus [1] - There was significant effort invested in these deals in the past, indicating that the decision to divest is strategic rather than impulsive [1]

Core Insights - Medtronic Plc reported second-quarter earnings and announced key board appointments following Elliott Investment Management becoming the largest shareholder [1] - The company introduced a new Growth Committee to oversee strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business [1] Financial Performance - Medtronic's first-quarter 2026 sales reached $8.58 billion, exceeding the consensus estimate of $8.38 billion, representing an 8.4% year-over-year increase with organic growth of 4.8% [2] - Adjusted earnings per share were $1.26, surpassing expectations of $1.23 [2] Sales Guidance - The company raised its sales guidance for fiscal 2026 from a range of $35.15 billion to $35.25 billion to a new range of $35.72 billion to $35.82 billion, compared to the consensus of $35.32 billion [3] Analyst Reactions - Needham's analyst Mike Matson believes Medtronic is in the early stages of a strong product cycle and expects Elliott's involvement to enhance shareholder value, but maintains a Hold rating until organic growth shows meaningful acceleration beyond 5% [4] - Matson raised fiscal 2026 and 2027 revenue estimates to $35.81 billion from $35.29 billion and to $37.69 billion from $36.96 billion, respectively [5] - Bernstein maintains an Outperform rating on Medtronic, raising the price forecast from $97 to $98, while Baird maintains a Neutral rating, increasing the price forecast from $94 to $96 [6] Stock Performance - Medtronic's stock increased by 4.07%, reaching $93.56 at the last check on Wednesday [6]